# Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures

Study · id `cardio:ct-nct05292846` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05292846](<https://clinicaltrials.gov/study/NCT05292846>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05292846

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT05292846. Allocation not applicable; no masking; primary purpose prevention. Start 2022-01-20 (actual); primary completion 2024-02-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT05292846, source copy `cardio:ctgov-nct05292846-2024-01-26`, retrieved 2026-10-26)
- Started: 2022-01-20 (actual) (ClinicalTrials.gov record NCT05292846, source copy `cardio:ctgov-nct05292846-2024-01-26`, retrieved 2026-10-26)
- Primary completion: 2024-02-20 (anticipated) (ClinicalTrials.gov record NCT05292846, source copy `cardio:ctgov-nct05292846-2024-01-26`, retrieved 2026-10-26)
- Completion: 2024-04-20 (anticipated) (ClinicalTrials.gov record NCT05292846, source copy `cardio:ctgov-nct05292846-2024-01-26`, retrieved 2026-10-26)
- Countries: Italy; Spain (ClinicalTrials.gov record NCT05292846, source copy `cardio:ctgov-nct05292846-2024-01-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05292846-2024-01-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
- Acronym: DOAC-NOSTOP
- Condition: Coronary Artery Disease
- Condition: Bleeding
- Condition: Direct Acting Anticoagulant Adverse Reaction
- Intervention (Drug): Direct-acting oral anticoagulation
- Lead sponsor: Hospital Universitario La Fe
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Hospital Universitario La Fe (`cardio:org-hospital-universitario-la-fe`)

## Provenance

Content hash: 78cf7e02eee295d31e7b25782f98040fffbe39eebd58675df450ba136685d8d7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
